Citations

Clear

15 citation(s) found for "Hines, Jolaine".

Enhancement of In Vitro hPTH1-84 Bioactivity by hPTH38-84 and hPTH45-84
Losbanos, Louis, Hines, Jolaine M., Singh, Ravinder , Kritmetapak, Kittrawee , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 200-201

10.1681/asn.20213210s1200d Get It

Chemical Characterization and Quantitation of Circulating Intact Parathyroid Hormone and Parathyroid Hormone Fragments by High-Resolution Mass Spectrometry in Chronic Renal Failure
Losbanos, Louis, Hines, Jolaine M., O’Grady, Katherine , Vesper, Hubert W. , Kritmetapak, Kittrawee , Ulmer, Candice Z. , Enders, Felicity , Singh, Ravinder J. , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 158-158

10.1681/asn.20203110s1158a Get It

Hyperphosphatemia with Elevated Serum FGF-23 and PTH, Reduced Calcitriol, and Normal FGF7 Concentrations Characterizes Chronic Renal Failure in Humans
Losbanos, Louis, Berent, Taylor E. , Ashrafzadeh‐Kian, Susan , Hines, Jolaine M., Kritmetapak, Kittrawee , Algeciras‐Schimnich, Alicia , Singh, Ravinder J. , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 162-162

10.1681/asn.20203110s1162a Get It

Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity
Waldron, Richard T. , Jones, Elaina K. , Anani, Vincent, Hines, Jolaine M., Lugea, Aurelia, Diniz, Márcio A. , Kim, Sungjin , Habtezion, Aida , Hoffman, Kristi L. , Petrosino, Joseph F. , Fisher, William E., Li, Liang , Lennon, Ryan J. , Vege, Santhi Swaroop , Topazian, Mark , Zhao, Jing , Singh, Ravinder Jit, Diniz, Marcio A , Waldron, Richard T , Zhao, Jing , Lennon, Ryan J. , Singh, Ravinder J. , Pandol, Stephen J.

Mayo Clinic

Pancreas | November 17, 2022 | Volume: 51 | Issue: 7 | Pages: 723-732

10.1097/mpa.0000000000002113 | PMID 36395395 Get It

Objectives Chronic pancreatitis (CP) is a chronic fibroinflammatory condition of the pancreas difficult to diagnose in early stages. Novel biomarkers useful to facilitate early diagnosis or treatment responses may be found in biofluids. Although saliva can be easily and noninvasively collected from patients, useful salivary biomarkers from CP patients have not yet been identified. Methods Here, we analyzed the proteome by quantitative proteomics, cytokine/chemokine levels by Luminex analysis, prostaglandin E2 (PGE2) levels by a mass spectrometry-based assay, and bacterial species diversity by 16S ribosomal ribonucleic acid sequencing in saliva samples from confirmed CP patients and healthy controls. Results Our results indicate the presence of various differentially expressed proteins, cytokines/chemokines, and a loss of oral bacterial diversity in the saliva of CP patients. The PGE2 levels trend toward elevation in CP patients. Area under the receiver operating characteristic curve models for proteomic, cytokine, and PGE2 assays ranged from 0.59 to 0.90. Conclusions Collectively, our studies identify a range of putative CP biomarkers and alterations in human saliva requiring further validation. The biomarker discovery approaches we used might lead to identification of biomarkers useful for CP diagnosis and monitoring.
Challenges in Translating Clinical Metabolomics Data Sets from the Bench to the Bedside
Ulmer, Candice Z. , Hines, Jolaine, Maus, Anthony , Singh, Ravinder J.

Mayo Clinic

Clinical Chemistry | October 6, 2021 | Volume: 67 | Issue: 12 | Pages: 1581-1583

10.1093/clinchem/hvab210 | PMID 34718477 Get It

Chemical Characterization and Quantification of Circulating Intact PTH and PTH Fragments by High-Resolution Mass Spectrometry in Chronic Renal Failure
Kritmetapak, Kittrawee , Losbanos, Louis, Hines, Jolaine M., O’Grady, Katherine , Ulmer, Candice Z. , Vesper, Hubert W. , Losbanos, Louis A, O'Grady, Katherine L, Enders, Felicity T, Enders, Felicity , Singh, Ravinder J. , Kumar, Rajiv

Mayo Clinic

Clinical Chemistry | January 20, 2021 | Volume: 67 | Issue: 6 | Pages: 843-853

10.1093/clinchem/hvab013 | PMID 33693557 Get It

Abstract Background The precise concentrations of full-length parathyroid hormone (PTH1-84) and the identity and concentrations of PTH fragments in patients with various stages of chronic renal failure are unknown. Methods We developed a liquid chromatography-high resolution mass spectrometry (LC-HRMS) method to characterize and quantify PTH1-84 and PTH fragments in serum of 221 patients with progressive renal dysfunction. Following capture by matrix-bound amino-terminal or carboxyl-terminal region-specific antibodies and elution from matrix, PTH1-84 and PTH fragments were identified and quantitated using LC-HRMS. PTH was simultaneously measured using an intact PTH (iPTH) immunoassay. Results Full-length PTH1-84 and 8 PTH fragments (PTH28-84, 34-77, 34-84, 37-77, 37-84, 38-77, 38-84, and 45-84) were unequivocally identified and were shown to increase significantly when an eGFR declined to ≤17-23 mL/min/1.73m2. Serum concentrations of PTH1-84 were similar when measured by LC-HRMS following capture by amino-terminal or carboxyl-terminal immunocapture methods. In patients with an eGFR of <30 mL/min/1.73 m2, serum PTH concentrations measured using LC-HRMS were significantly lower than PTH measured using an iPTH immunoassay. PTH7-84 and oxidized forms of PTH1-84 were below the limit of detection (30 and 50 pg/mL, respectively). Conclusions LC-HRMS identifies circulating PTH1-84, carboxyl-terminal PTH fragments, and mid-region PTH fragments, in patients with progressive renal failure. Serum PTH1-84 and its fragments markedly rise when an eGFR decreases to ≤17-23 mL/min/1.73 m2. PTH concentrations measured using LC-HRMS tend to be lower than those measured using an iPTH immunoassay, particularly in severe chronic renal failure. Our data do not support the existence of circulating PTH7-84 and oxidized PTH1-84.
Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes
Eckhardt, Brittany, Rowsey, Jennifer L. , Thicke, Brianne S, Fraser, Daniel G., O’Grady, Katherine , Bondar, Olga P., Hines, Jolaine M., Thoreson, Andrew R. , Rakshit, Kuntol, Lagnado, Anthony B. , Passos, João F. , Matveyenko, Aleksey V. , Farr, Joshua N. , Passos, João F , Singh, Ravinder , Vella, Adrian , Khosla, Sundeep , Monroe, David G.

Mayo Clinic

JCI Insight | April 8, 2020 | Volume: 5 | Issue: 9 | Pages: No page available

10.1172/jci.insight.135236 | PMID 32267250 Get It

The worldwide prevalence of type 2 diabetes (T2D) is increasing. Despite normal to higher bone density, patients with T2D paradoxically have elevated fracture risk resulting, in part, from poor bone quality. Advanced glycation endproducts (AGEs) and inflammation as a consequence of enhanced receptor for AGE (RAGE) signaling are hypothesized culprits, although the exact mechanisms underlying skeletal dysfunction in T2D are unclear. Lack of inducible models that permit environmental (in obesity) and temporal (after skeletal maturity) control of T2D onset has hampered progress. Here, we show in C57BL/6 mice that a onetime pharmacological intervention (streptozotocin, STZ) initiated in adulthood combined with high-fat diet–induced (HFD-induced) obesity caused hallmark features of human adult-onset T2D, including prolonged hyperglycemia, insulin resistance, and pancreatic β cell dysfunction, but not complete destruction. In addition, HFD/STZ (i.e., T2D) resulted in several changes in bone quality that closely mirror those observed in humans, including compromised bone microarchitecture, reduced biomechanical strength, impaired bone material properties, altered bone turnover, and elevated levels of the AGE CML in bone and blood. Furthermore, T2D led to the premature accumulation of senescent osteocytes with a unique proinflammatory signature. These findings highlight the RAGE pathway and senescent cells as potential targets to treat diabetic skeletal fragility.
Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes
O’Grady, Katherine , Bondar, Olga P., Atkinson, Elizabeth J. , Achenbach, Sara J., Eckhardt, Brittany, Thicke, Brianne S, Tweed, Amanda, Volkman, Tammie L., Hines, Jolaine M., O'Grady, Katherine L, Farr, Joshua N. , Eckhardt, Brittany A, Tweed, Amanda J, Drake, Matthew T. , Khosla, Sundeep , Singh, Ravinder J.

Mayo Clinic

The Journal of Applied Laboratory Medicine | January 29, 2020 | Volume: 5 | Issue: 3 | Pages: 558-568

10.1093/jalm/jfaa023 | PMID 32445362 Get It

AbstractBackgroundAdvanced glycation end products (AGEs) are formed via the nonenzymatic glycation of sugars with amino acids. Two AGEs, Nε-(1-carboxymethyl)-L-Lysine (CML) and pentosidine, have been observed to be elevated in subjects suffering from a multitude of chronic disease states, and accumulation of these compounds may be related to the pathophysiology of disease progression and aging.MethodsWe describe here the development and validation of a specific and reproducible LC-MS/MS method to quantify CML and pentosidine in human serum with lower limits of quantitation of 75 ng/mL and 5 ng/mL, respectively. The analyte calibration curve exhibited excellent linearity at a range of 0–10 900 ng/mL for CML and 0–800 ng/mL for pentosidine. High-low linearity of 5 serum pairs was assessed, with a mean recovery of 103% (range 94—116%) for CML, and 104% (range 97—116%) for pentosidine.ResultsSerum concentrations of CML and pentosidine were quantified in 30 control and 30 subjects with chronic renal insufficiency. A significant increase in both analytes was observed in renal failure compared to control subjects (2.1-fold and 8.4-fold, respectively; P < 0.001 for both). In a separate cohort of 49 control versus 95 subjects with type 2 diabetes mellitus (T2DM), serum CML but not serum pentosidine, was significantly elevated in the T2DM patients, and CML was also correlated with glycemic control, as assessed by hemoglobin A1c (r = 0.34, P < 0.001).ConclusionsThese mass spectroscopy-based assays for serum CML and pentosidine should be useful in accurately evaluating circulating levels of these key AGEs in various disease states.
Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty
Hines, Jolaine, Hernandez, N. M., Amundson, Adam W. , Pagnano, Mark W. , Sierra, Rafael J. , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | May 31, 2019 | Volume: 101-B | Issue: 6_Supple_B | Pages: 104-109

10.1302/0301-620x.101b6.bjj-2018-1376.r1 | PMID 31146563 Get It

Aims Tranexamic acid (TXA) has been shown to significantly reduce transfusion rates in primary total hip arthroplasties (THAs), but high-quality evidence is limited in the revision setting. The purpose of the current study was to compare the rate of blood transfusions and symptomatic venous thromboembolic events (VTEs) in a large cohort of revision THAs treated with or without intravenous (IV) TXA. Patients and Methods We performed a retrospective review of 3264 revision THAs (2645 patients) between 2005 and 2014, of which 1142 procedures received IV TXA (1 g at incision and 1 g at closure). The mean age in the revision group with TXA was 65 years (28 to 95), with 579 female patients (51%). The mean age in the revision group treated without TXA was 67 years (21 to 98), with 1160 female patients (55%). Outcomes analyzed included rates of transfusion and symptomatic VTEs between procedures undertaken with and without TXA. These comparisons were performed for the overall cohort, as well as within cases subcategorized for aseptic or septic aetiologies. A propensity score was developed to minimize bias between groups and utilized age at revision THA, sex, body mass index, American Society of Anesthesiologists (ASA) score, preoperative anticoagulation, and year of surgery. Results Tranexamic acid significantly and substantially reduced the rate of blood transfusions after revision THA overall from 54% to 26% (p < 0.001; adjusted relative risk (RR) 1.6; 95% confidence interval (CI) 1.3 to 1.9), with a significant reduction in both aseptic (49% to 18%; p < 0.001) and septic (73% to 53%; p = 0.04) revisions. The rate of VTE was minimal overall, with three events (0.3%) in the TXA group and four events (0.2%) in the non-TXA group. There were no significant differences in VTE rates based on TXA use or aetiology of revision. Conclusion Intravenous TXA significantly reduced transfusion rates during all-cause revision THAs, including a subgroup analysis of both aseptic and septic cohorts. Adjusted risk using propensity modelling showed no statistical difference in rates of VTEs between either group. Cite this article: Bone Joint J 2019;100-B(6 Supple B):104–109.
Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature
Kaur, Ravinder Jeet , Pichurin, Pavel N. , Hines, Jolaine M., Grebe, Stefan K., Singh, Ravinder J. , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | March 5, 2019 | Volume: 3 | Issue: 4 | Pages: 784-790

10.1210/js.2019-00050 | PMID 30963136 Get It